Pharma channel feed – Endpoints News

Pharma channel feed

FDA experts offer a unanimous endorsement for Spark’s pioneering AAV gene therapy for blindness

8 years ago

Karyopharm bags a $193M Asian deal for selinexor and followup drug, shares jump

8 years ago

In a new setback, FDA kicks back AcelRx’s application for pain med — shares tank again

8 years ago

J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide

8 years ago

Battered by mixed PhIII data, Trevena axes R&D staff and hunkers down around lead pain drug

8 years ago

The FDA's insider view on Aerie’s glaucoma drug: Yes on efficacy, but…

8 years ago

Ten big lobbying groups turn their guns on Allergan's controversial patent gambit

8 years ago

With just a little encouragement, biotech investors are ready to fall in love again

8 years ago

Scott Gottlieb likes his job running the FDA, but he isn't ruling out a big HHS promotion

8 years ago

Giant Merck buddies up with little KalVista on lead drug, igniting stock with a $760M deal

8 years ago

AbbVie jumps on the oncolytics bandwagon, embracing Turnstone in new collaboration

8 years ago

Spark Therapeutics faces a grilling as FDA ponders a pioneering OK for gene therapy

8 years ago

Biotech scientist/entrepreneur Saurabh Saha makes an unusual return to the arms of a big — and excessively discreet — R&D group

8 years ago

Flexion nabs FDA OK for its potential blockbuster osteoarthritis drug, triggering new buyout buzz

8 years ago

Facing an exodus, EMA starts to line up temp replacements as top staffers jump ship

8 years ago

Faster, pricier and often worthless: Study slams regulators for wave of questionable cancer drug OKs

8 years ago

FDA offers surprise OK for Mylan’s Copaxone knockoffs, slamming Teva

8 years ago

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

8 years ago

Amgen comes up with $1.5B package to partner with CytomX on a preclinical Probody approach to cancer

8 years ago

Patients often demand experimental drugs that prove ineffective — report

8 years ago

Celgene joins the heavyweight partner club collaborating with Nimbus

8 years ago

Sam Kulkarni takes the helm at CRISPR Therapeutics as founding CEO steps down

8 years ago

In the wake of a drubbing, Vivek Ramaswamy gambles $116M on Arbutus’ hep B work

8 years ago

Eli Lilly R&D chief Jan Lundberg heads for the exit as CEO assembles a new team at the top

8 years ago

First page Previous page 312 313 314315316 317 318 Next page Last page